On February 8, 2022, Denovicon Therapeutics Founder & CEO, Scott Bembenek will talk (along with BIOVIA’s Ton van Daelen) at SLAS 2022 about how AI and the use of virtual–real cycles is changing the drug discovery process.
Denovicon was pleased to participate in BIO Partnering at JPM 2022. If you’re interested in learning more about our AI/machine learning/molecular modeling platform and current molecular assets, feel free to reach out.
On September 14, 2021, Denovicon Therapeutics Founder & CEO, Scott Bembenek, presented on Denovicon’s ‘AI–Molecular Modeling Platform for Enhanced Small-Molecule Drug Discovery’ at the Biovia User Group Meeting 2021.
On November 16, 2020, Denovicon Therapeutics Founder & CEO, Scott Bembenek, spoke at the Global Pharma R&D AI, Data Science and Informatics Summit (PRADI 2020) on ‘Combining Machine Learning and Molecular Modeling for Enhanced Active Learning in...
On November 5, 2020, Denovicon Therapeutics Founder & CEO, Scott Bembenek, took part in the Lab of the Future panel entitled ‘Strategies for Accelerating Drug Discovery with AI.’
On July 14, 2020, Denovicon Therapeutics Founder & CEO, Scott Bembenek, shared some of his experiences and insights from his scientific and entrepreneurial journeys (thus far) with Rady and UCSD students at Rady’s Careers in Biotech Panel.
